Bio & Medicine
Kyung Nam Pharm shares suspended over alleged accounting irregularities
- PUBLISHED :March 02, 2018 - 15:14
- UPDATED :March 02, 2018 - 15:14
[THE INVESTOR] The Korea Exchange on March 2 suspended trading of Kyung Nam Pharm shares, putting it under review over the drug maker’s alleged accounting irregularities.
The suspension, which will be effective until March 23, comes after the Securities and Futures Commission on Feb. 28 filed a complaint against the KOSDAQ-listed company for inflating revenue figures and using faulty accounting practices.
By Park Han-na (firstname.lastname@example.org)